Roche Aktie - 1RO

Roche Holding AG (1RO) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

( - )

Gebot

Fragen

Volumen

0,00 Tagesbereich 0,00

270,00 52-Wochen-Bereich 422,00

Marktkapitalisierung

Handelsende

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

1.021.782 €

Ausgegebene Aktien

795.617.637

Dividendenrendite (LTM)

9,8 (3,11%)

Kurs-Gewinn-Verhältnis

20,39

Gewinn pro Aktie (EPS)

16,04

Erlöse (LTM)

63,36B

Nettogewinn (LTM)

12,88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland. Mehr anzeigen

Sektor

Branche

Website

www.roche.com

Hauptsitz

Basel, Switzerland

Gegründet

1896

Roche Holding AG is listed in the sector of the Italienische Börse with ticker 1RO. The last closing price for Roche was -. Over the last year, Roche shares have traded in a share price range of 270,00 € to 422,00 €.

Roche currently has 795.617.637 shares in issue. Roche has a price to earnings ratio (PE ratio) of 20.39.

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer Filing acceptance is based on the phase III Alliance...

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg...

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive...

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions Late-breaking Phase II...

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management Roche introduces the...

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer New...

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) Elecsys® pTau217...

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics PathAI’s best-in-class Image Management...

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 New real-world data confirm Vabysmo’s potent...

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	346.8	362.8	346.8	6	360.03870968	DE
4	362.8	377	341.6	33	359.45369532	DE
12	338	377.8	338	23	357.11207577	DE
26	350	422	334	18	367.70884146	DE
52	308	422	270	13	351.09809912	DE
156	306	422	270	12	350.17560813	DE
260	306	422	270	12	350.17560813	DE

1RO - Frequently Asked Questions (FAQ)

What is the current Roche Holding AG share price?

The current share price of Roche Holding AG is 0,00 €

How many Roche Holding AG shares are in issue?

Roche Holding AG has 795.617.637 shares in issue

What is the 1 year trading range for Roche Holding AG share price?

Roche Holding AG has traded in the range of 270,00 € to 422,00 € during the past year

What is the PE ratio of Roche Holding AG?

The price to earnings ratio of Roche Holding AG is 20,39

What is the cash to sales ratio of Roche Holding AG?

The cash to sales ratio of Roche Holding AG is 4,12

What is the registered address of Roche Holding AG?

The registered address for Roche Holding AG is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holding AG website address?

The website address for Roche Holding AG is www.roche.com

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holding AG (1RO)

Roche Holding AG (1RO) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Roche Holding AG

1RO Neueste Nachrichten

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

1RO - Frequently Asked Questions (FAQ)

1RO Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen